Granules India lines capex of Rs 1,000 crIllustrative image – not actual.
Granules India has earmarked a capital expenditure (capex) of around Rs 1,000 crore which it aims to invest by FY22-24 on expansion of operations.
 
The company plans to invest on a new manufacturing facility and on expanding production capacities at the existing plants.
 
During FY22, the company expects to spend Rs 400 crore and the remaining Rs 600 crore is spread over FY23 and FY24.
 
The drug firm plans to infuse around Rs 180 crore on a multiple units pellet system (MUPS) block, around Rs 250 crore on expanding active pharmaceutical ingredients (API) capacity, Rs 320 crore on a new formulation plant and another Rs 30 crore on expansion of a facility near Hyderabad which rolls out paracetamol and metformin. 
 
The company also aims to invest in the range of Rs 150 crore on research and development (R&D) activities every year.
 
Going forward, the company plans on spending about a minimum of Rs 150 crore every year.

 

← All latest storiesBack to top →